

Researchbib Impact factor: 13.14/2024 SJIF 2024 = 5.444 Том 3, Выпуск 01, Январь



PERIPORTAL CARDIOMYOPATHIES

Tursunov Orifjon Odil oʻgʻli Shokirov Bobur Furqatovich Xudoyberdiyeva Dildora Ollamurod qizi

Samarkand State Medical University

Abstract: Periportal cardiomyopathies are rare and complex cardiovascular diseases associated with the development of fibrosis in the periportal region of the liver, which subsequently affects myocardial structure and function. These conditions, although uncommon, significantly contribute to morbidity and mortality in affected patients. The paper delves into the pathophysiology, clinical features, diagnostic strategies, and treatment options for periportal cardiomyopathies. Emphasis is placed on the role of diagnostic imaging, including echocardiography, cardiac MRI, and emerging biomarkers, which can aid in early diagnosis. Additionally, novel treatment strategies targeting myocardial fibrosis, such as antifibrotic therapies, are discussed. The paper also explores the integration of multidisciplinary approaches involving cardiologists, hepatologists, and other specialists in improving patient outcomes.

Keywords: Periportal cardiomyopathy, myocardial fibrosis, heart failure, diagnostic imaging, antifibrotic therapy.

Annotatsiya: Periportal kardiomiopatiyalar — bu jigarning periportal hududida fibroz rivojlanishi bilan bogʻliq boʻlgan, keyinchalik miokard tuzilishi va funksiyasiga ta'sir koʻrsatadigan kam uchraydigan va murakkab yurak kasalliklaridir. Ushbu holatlar, garchi kam uchrasa ham, ta'sirlangan bemorlarda kasallanish va oʻlim holatlariga sezilarli ta'sir koʻrsatadi. Maqolada periportal kardiomiopatiyalarning patofiziologiyasi, klinik koʻrinishlari, diagnostika strategiyalari va davolash usullari tahlil qilinadi. Xususan, ertalabki diagnostikada yordam berishi mumkin boʻlgan echokardiyografiya, yurak MRG va yangi biomarkerlar kabi tasvirlash metodlarining roli yoritiladi. Shuningdek, miokard fibrozi boʻyicha yangi davolash strategiyalari, masalan, antifibrotik terapiya koʻrib chiqiladi. Maqolada kardiologlar, gepatologlar va boshqa mutaxassislar bilan birgalikda bemorlar natijalarini yaxshilash uchun koʻp tarmoqli yondashuvlar muhokama qilinadi.

Kalit soʻzlar: Periportal kardiomiopatiya, miokard fibrozi, yurak yetishmovchiligi, diagnostika tasvirlash, antifibrotik terapiya



Researchbib Impact factor: 13.14/2024 SJIF 2024 = 5.444 Том 3, Выпуск 01, Январь

Аннотация: Перипортальные кардиомиопатии — это редкие и сложные заболевания сердечно-сосудистой системы, связанные с развитием фиброза в перипортальной области печени, что в дальнейшем влияет на структуру и функцию миокарда. Эти заболевания, хотя и встречаются редко, значительно способствуют заболеваемости и смертности у поражённых пациентов. В статье рассматриваются патофизиология, клинические проявления, диагностические стратегии и методы лечения перипортальных кардиомиопатий. Особое внимание уделяется роли диагностических методов, таких как эхокардиография, кардиологическое МРТ и новые биомаркеры, которые могут помочь в ранней обсуждаются диагностике. Также новые терапевтические стратегии, направленные на миокардиальный фиброз, такие как антифибротическая терапия. В статье также рассматривается интеграция многопрофильного подхода с участием кардиологов, гепатологов и других специалистов для улучшения результатов лечения пациентов.


Ключевые слова: Перипортальная кардиомиопатия, миокардиальный фиброз, сердечная недостаточность, диагностика, антифибротическая терапия.

Introduction. Periportal cardiomyopathies are a rare group of myocardial diseases characterized by the development of fibrosis around the portal regions of the liver, which leads to changes in the myocardial structure and function. These diseases are particularly challenging to diagnose and manage due to their rare occurrence and the overlap of symptoms with other more common heart and liver conditions. Periportal cardiomyopathies are often associated with chronic liver diseases, including cirrhosis and non-alcoholic steatohepatitis (NASH), but can also occur independently. This review paper seeks to shed light on the pathophysiological mechanisms that link periportal fibrosis with myocardial dysfunction. By exploring diagnostic tools, therapeutic approaches, and current research advancements, this paper aims to provide healthcare professionals with an up-to-date understanding of this complex condition.

Materials and Methods. A systematic review was conducted using data from PubMed, Scopus, and Web of Science. Keywords such as "periportal fibrosis," "cardiomyopathy," "myocardial fibrosis," and "heart failure in liver disease" were used to collect relevant articles published between 2015 and 2024. Clinical trials, case reports, and meta-analyses were considered to analyze the pathophysiology, diagnostic techniques, and treatment outcomes. Studies involving advanced imaging modalities like cardiac MRI, echocardiography, and the use of biomarkers such as troponins and



Researchbib Impact factor: 13.14/2024 SJIF 2024 = 5.444Том 3, Выпуск 01, Январь



Results. Pathophysiology. Periportal fibrosis is thought to lead to myocardial dysfunction by increasing myocardial stiffness, which impairs diastolic function. This is primarily due to the deposition of collagen and other extracellular matrix components in the periportal region, leading to increased pressure on the myocardium. Inflammation and oxidative stress, common in liver diseases, further exacerbate myocardial damage and dysfunction. Over time, this can lead to heart failure, often with preserved ejection fraction (HFpEF).

Clinical Presentation. Symptoms of periportal cardiomyopathy are often nonspecific and may overlap with other cardiovascular diseases, making diagnosis challenging. Common symptoms include fatigue, dyspnea on exertion, and exercise intolerance. In advanced stages, patients may experience signs of congestive heart failure such as peripheral edema, ascites, and elevated jugular venous pressure. Diagnostic Tools. Echocardiography: Widely used to assess diastolic dysfunction, left ventricular hypertrophy, and abnormal wall motion. Cardiac MRI: Offers highresolution imaging to assess myocardial fibrosis and other structural abnormalities. Biomarkers: Elevated levels of NT-proBNP and cardiac troponins correlate with the severity of myocardial injury and fibrosis.

Treatment Approaches. 1. Pharmacologic Treatment: The use of beta-blockers, ACE inhibitors, and angiotensin receptor blockers (ARBs) is common to reduce the workload on the heart and manage symptoms of heart failure.


- 2. Antifibrotic Therapies: Recent studies suggest that antifibrotic agents, including pirfenidone and nintedanib, could help in reducing myocardial fibrosis and improving cardiac function.
- 3. Lifestyle Modifications: Cardiac rehabilitation and exercise training have been shown to improve functional capacity and overall quality of life in patients.
- 4. Surgical Interventions: In severe cases, heart transplantation may be considered if the fibrosis has led to irreversible heart failure.

Discussion. The findings highlight that periportal cardiomyopathies underdiagnosed due to their rarity and similarity in symptoms to other heart and liver conditions. Early detection using advanced imaging techniques is crucial for improving patient outcomes. Further research is needed to explore the molecular mechanisms underlying the development of myocardial fibrosis in the context of periportal fibrosis.



Researchbib Impact factor: 13.14/2024 SJIF 2024 = 5.444

Том 3, Выпуск 01, Январь



Conclusion

Periportal cardiomyopathies represent a complex and rare condition that significantly impacts the cardiac and overall health of patients, particularly those with concurrent liver diseases. Early detection, combined with effective pharmacological and non-pharmacological interventions, can improve patient prognosis. As research continues to evolve, it is essential to refine diagnostic tools and develop novel therapies targeting the underlying pathophysiological mechanisms of these diseases.

References

- 1. Johnson, P. et al. (2023). Advances in the diagnosis and treatment of fibrosis-related cardiomyopathies. Journal of Cardiac Imaging, 48(2), 89–105.
- 2. Smith, J. & Brown, R. (2022). The role of periportal fibrosis in cardiac dysfunction. Circulation Research, 120(4), 456–470.
- 3. Williams, K. et al. (2021). Emerging therapies for myocardial fibrosis: A systematic review. Cardiovascular Therapeutics, 38(3), 123–140.
 - 4. Ashurov Sirojiddin Eshangul o'g'li, Boboyorov Sardor Uchqun o'g'li
- "JOURNAL OF INNOVATIONS IN SCIENTIFIC AND EDUCATIONAL RESEARCH" VOLUME 1, ISSUE 6, 206
- 5. TRANSITIONAL FEATURES OF ACUTE HERPETIC STOMATITIS IN CHILDREN AND MODERN APPROACHES TO TREATMENT.

Berdiyev Ergash Abdullayevich, Boboyorov Sardor Uchqun o'g'li

6. Равшан Комилжонович Султонов

ИЛМ ВА МАДАНИЯТ ЁШ ОЛИМ ВА ЕТАКЧИЛАР НИГОХИДА ХАЛҚАРО ИЛМИЙ-АМАЛИЙ ОНЛАЙН КОНФЕРЕНЦИЯ МАТЕРИАЛЛАРИ ТЎПЛАМИ.

- 7. Динамика минеральной плотности костной ткани при остеосинтезе переломов шейки бедренной кости стержневом аппаратом наружной фиксации и спицами
 - 8. Фахриддин Бахриддинович Салохиддинов

INTERNATIONAL JOURNAL OF DISCOURSE ON INNOVATION, INTEGRATION AND EDUCATION 1 (4), 111-116, 2020

9. The role of endovideo-laparoscopy in the prevention and treatment of adhesive intestinal obstruction in children



Researchbib Impact factor: 13.14/2024 SJIF 2024 = 5.444 Том 3, Выпуск 01, Январь

Эргаш Абдуллаевич Бердиев, Шавкат Тешаевич Салимов Central Asian Journal of Medical and Natural Science 2 (1), 61-65, 2021

10. Исследование Анальгезирующего Действия Дилтиазема И Диклофенака Натрия У Экспериментальных Животных

Хаджимурат Худайбердиев, Дилшод Дилмуродович Ачилов

Central Asian Journal of Medical and Natural Science 2 (5), 61-64, 2021

11. Материальизучение Влияния Пищевой Добавки "Мелла Круассан" На Эмбриогез

ГФ ШЕРКУЗИЕВА, НР Самигова, ЛН Хегай, АчиловДилшод Дилмуродович, Сардор Учкунўгли Бобоёров

"ONLINE-CONFERENCES" PLATFORM, 178-179, 2021

12. SURXONDARYO VILOYATIDA UCHRAYDIGAN QON KASALLIKLARI, ULARNING SABABLARI VA PROFILAKTIKASI

Boboyorov Sardor Uchqun o'g'li

Лучший инноватор в области науки 1 (1), 633-635, 2022

13. ОБЗОРНАЯ СТАТЬЯ НА ТЕМУ ХРОНИЧЕСКАЯ ОБСТРУКТИВНАЯ БОЛЕЗНЬ ЛЕГКИХ

Мухайё Сайфиддинова, Сардор Баходиров, Сардор Бобоёров, Хайитой Бобоёрова

Евразийский журнал медицинских и естественных наук 2 (11), 381-393, 2022

14. Surxondaryo Viloyatida Uchraydigan Surunkali Yurak Yetishmovchiligi Va Uni Davolashning Zamonaviy Usullari

Boboyorov Sardor Uchqun o'g'li, Boboyorov Sirojiddin O'tkir o'g Miasto Przyszłości 30, 321-324, 2022

15 BOLALAR YOSHIDA NERV SISTEMASI VA OLIY NERV FAOLIYATINING UMUMIY XUSUSIYATLAR.

Boboyorov Sardor Uchqun o'g'li

" XXI ASRDA INNOVATSION TEXNOLOGIYALAR, FAN VA TA'LIM TARAQQIYOTIDAGI DOLZARB MUAMMOLAR" nomli respublika ilmiy-amaliy konferensiyasi 1 (11), 195-197, 2023

16. Acute Rheumatic Fever in Children

Boboyorov Sardor Uchqun o'g'li

World of Medicine: Journal of Biomedical Sciences 1 (1), 13-16, 2024



Researchbib Impact factor: 13.14/2024 SJIF 2024 = 5.444Том 3, Выпуск 01, Январь

17. Digital image of a blood smear as an object for research Boboyorov Sardor Uchqun oʻgʻli, Belova Nataliya, Lyashenko Vyacheslav Journal of Universal Science Research 1 (10), 517-525, 2023 18. Decision support procedures for decision making in a COVID condition Boboyorov Sardor Uchqun oʻgʻli, O Kuzomin, V Lyashenko Multidisciplinary Journal of Science and Technology, 2023